Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.71 |
| ▸ | CA2 | P00918 | 9/20 | 0.71 |
| ▸ | CA9 | Q16790 | 4/20 | 0.71 |
| ▸ | CA12 | O43570 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037960 | 0.93 | CA1 (0.61) | CA1CA2CA9CA12POLB | |
| SCHEMBL6037974 | 0.83 | LMNA (0.59) | CA1CA2CA9CA12POLB | |
| SCHEMBL6037903 | 0.81 | CA1 (0.49) | CA1CA2CA9CA12POLB | |
| SCHEMBL6037885 | 0.80 | LMNA (0.55) | CA1CA2CA9CA12POLB | |
| SCHEMBL5280853 | 0.79 | LMNA (0.68) | POLBALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL6038132 | 0.79 | ALDH1A1 (0.51) | CA1CA2CA9CA12POLB | |
| SCHEMBL6038163 | 0.78 | LMNA (0.49) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL6038064 | 0.78 | LMNA (0.49) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL5281557 | 0.77 | LMNA (0.50) | ALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL5325209 | 0.77 | LMNA (0.51) | ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | CA1 1431/4885CA2 2233/4885CA9 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.